Nurulimab/Prolgolimab

N/A

Report date: 2025/01/10 10:54:09

Base Information

Drug NameNurulimab/Prolgolimab
Drug Alias NameProlgolimab/NurulimabNurulimab + ProlgolimabBCD-217BCD-145/BCD-100
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSkin MelanomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian FederationBelarusIndia
CombinationsYes NurulimabProlgolimab
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsSkin MelanomaMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A